SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.
Investigated for use/treatment in hyperlipidemia.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.